VAX FACTS

DATE: August 7, 2017

Please Read and Post

INCREASED DOSAGE RECOMMENDED FOR INTRAMUSCULAR IMMUNE GLOBULIN FOR HEPATITIS A PRE- AND POST-EXPOSURE PROPHYLAXIS

The recommended dosage of human immunoglobulin (IG) for intramuscular administration has been increased to 0.1 mL/kg for pre- and post-exposure prophylaxis of Hepatitis A virus (HAV) infection – this is 5 times greater than the previously recommended dose.

- GamaSTAN® S/D (Grifols Therapeutics) is the only available formulation of human intramuscular (IM) immunoglobulin (IG) in the USA.
- In July 2017 Grifols increased the recommended dosages of GamaSTAN S/D for pre- and post-exposure prophylaxis of HAV infection. The dosages were changed based on reportedly lower concentrations of anti-HAV antibodies in the product due to decreasing prevalence of previous HAV infection among plasma donors.
- **Post-Exposure Prophylaxis.** Susceptible contacts exposed to HAV are recommended to receive a dose of single-antigen HAV vaccine and/or intramuscular IG as soon as possible within 2 weeks of last exposure. When intramuscular IG is indicated, the dose should be 0.1 mL/kg. For guidance in managing HAV exposures contact SFDPH Communicable Disease Control at (415) 554-2830.
- **Pre-Exposure Prophylaxis.** HAV vaccine is recommended for susceptible persons planning international travel to countries with endemic Hepatitis A; however, intramuscular IG may be used as pre-exposure HAV prophylaxis in infants age <12 months for whom vaccine is not approved, and for certain others (e.g. immune compromised persons who might not develop seroprotection after vaccination). The dose of intramuscular IG for pre-exposure HAV prophylaxis is 0.1 mL/kg for travel of duration up to one month, 0.2 mL/kg for duration up to two months, and repeated boosters of 0.2 mL/kg every two months for duration beyond two months.

CA Dept. Public Health Hepatitis A Info: [https://archive.cdph.ca.gov/HealthInfo/discond/Pages/HepatitisA.aspx](https://archive.cdph.ca.gov/HealthInfo/discond/Pages/HepatitisA.aspx)